The latest price target for MBX Biosciences (NASDAQ:MBX) was reported by Barclays on January 28, 2026. The analyst firm set a price target for $66.00 expecting MBX to rise to within 12 months (a possible 112.90% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for MBX Biosciences (NASDAQ:MBX) was provided by Barclays, and MBX Biosciences initiated their overweight rating.

There is no last upgrade for MBX Biosciences

There is no last downgrade for MBX Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MBX Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MBX Biosciences was filed on January 28, 2026 so you should expect the next rating to be made available sometime around January 28, 2027.

While ratings are subjective and will change, the latest MBX Biosciences (MBX) rating was a initiated with a price target of $0.00 to $66.00. The current price MBX Biosciences (MBX) is trading at is $31.00, which is within the analyst’s predicted range.